Veterinary medicine and science · 2026
Primary Peritoneal Perivesical Hemangiosarcoma in 16 Dogs (2020-2024).
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roca Jose, Escoda Xavier, García-de la Virgen Miguel, Rodríguez Ignasi
Аннотация
BACKGROUND: Canine hemangiosarcoma (HSA) commonly arises in the spleen, heart, and skin, whereas primary peritoneal presentations are rare and poorly characterized. A perivesical peritoneal location without involvement of adjacent organs has not been previously well described.
OBJECTIVE: This study aims to characterize the clinical presentation, diagnostic features, treatment, and outcomes of dogs with primary peritoneal perivesical HSA.
ANIMALS: This study included 16 client-owned dogs diagnosed with peritoneal perivesical HSA at 2 referral centres between 2020 and 2024.
METHODS: Methods consisted of retrospective multicentre case series. Medical records were reviewed for clinical signs, laboratory abnormalities, imaging findings, diagnostic procedures, treatment, metastatic status, and outcome measures, including progression-free survival (PFS) and disease-specific survival time (DSST).
RESULTS: Common presenting signs included lethargy, hyporexia, pale mucous membranes, and abdominal distension. Hemoperitoneum was identified in 50% of the dogs. Frequent laboratory abnormalities included anaemia, thrombocytopenia, neutrophilia, and azotaemia. All dogs had a mass adjacent to the urinary bladder without evidence of origin from surrounding organs. Diagnosis was achieved by cytology or histopathology. Metastatic disease was suspected at diagnosis in 56.25% of the dogs, most commonly affecting the lungs, and the overall metastatic rate was 87.5%. Treatment protocols included chemotherapy alone (n = 8), surgery with adjuvant chemotherapy (n = 7), and neoadjuvant chemotherapy followed by surgery (n = 1). All surgical procedures consisted of debulking surgery. Chemotherapy alone resulted in a 55.55% partial response rate. Mean PFS and DSST were both 125 days. Combination therapy, response to chemotherapy, and rescue treatment were significantly associated with improved DSST.
CONCLUSIONS: Primary peritoneal perivesical HSA may represent a distinct anatomical presentation of canine HSA. Multimodal treatment strategies may improve clinical outcomes and survival in affected dogs.
OBJECTIVE: This study aims to characterize the clinical presentation, diagnostic features, treatment, and outcomes of dogs with primary peritoneal perivesical HSA.
ANIMALS: This study included 16 client-owned dogs diagnosed with peritoneal perivesical HSA at 2 referral centres between 2020 and 2024.
METHODS: Methods consisted of retrospective multicentre case series. Medical records were reviewed for clinical signs, laboratory abnormalities, imaging findings, diagnostic procedures, treatment, metastatic status, and outcome measures, including progression-free survival (PFS) and disease-specific survival time (DSST).
RESULTS: Common presenting signs included lethargy, hyporexia, pale mucous membranes, and abdominal distension. Hemoperitoneum was identified in 50% of the dogs. Frequent laboratory abnormalities included anaemia, thrombocytopenia, neutrophilia, and azotaemia. All dogs had a mass adjacent to the urinary bladder without evidence of origin from surrounding organs. Diagnosis was achieved by cytology or histopathology. Metastatic disease was suspected at diagnosis in 56.25% of the dogs, most commonly affecting the lungs, and the overall metastatic rate was 87.5%. Treatment protocols included chemotherapy alone (n = 8), surgery with adjuvant chemotherapy (n = 7), and neoadjuvant chemotherapy followed by surgery (n = 1). All surgical procedures consisted of debulking surgery. Chemotherapy alone resulted in a 55.55% partial response rate. Mean PFS and DSST were both 125 days. Combination therapy, response to chemotherapy, and rescue treatment were significantly associated with improved DSST.
CONCLUSIONS: Primary peritoneal perivesical HSA may represent a distinct anatomical presentation of canine HSA. Multimodal treatment strategies may improve clinical outcomes and survival in affected dogs.